Cargando…

Neurological and psychiatric safety of tafenoquine in Plasmodium vivax relapse prevention: a review

BACKGROUND: Tafenoquine is an 8-aminoquinoline anti-malarial drug recently approved as a single-dose (300 mg) therapy for Plasmodium vivax relapse prevention, when co-administered with 3-days of chloroquine or other blood schizonticide. Tafenoquine 200 mg weekly after a loading dose is also approved...

Descripción completa

Detalles Bibliográficos
Autores principales:	Duparc, Stephan, Chalon, Stephan, Miller, Scott, Richardson, Naomi, Toovey, Stephen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071640/ https://www.ncbi.nlm.nih.gov/pubmed/32169086 http://dx.doi.org/10.1186/s12936-020-03184-x

Ejemplares similares

Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria
por: Llanos-Cuentas, A., et al.
Publicado: (2019)

Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria
por: Lacerda, M.V.G., et al.
Publicado: (2019)

Tafenoquine for preventing relapse in people with Plasmodium vivax malaria
por: Rajapakse, Senaka, et al.
Publicado: (2015)

Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping
por: Beck, Hans-Peter, et al.
Publicado: (2016)

Pharmacogenetic assessment of tafenoquine efficacy in patients with Plasmodium vivax malaria
por: St Jean, Pamela L., et al.
Publicado: (2020)

Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to date
por: Ebstie, Yehenew A, et al.
Publicado: (2016)

Tafenoquine for Plasmodium vivax malaria: Concerns regarding efficacy & safety
por: Sharma, Jatin, et al.
Publicado: (2021)

Relapses of Plasmodium vivax malaria threaten disease elimination: time to deploy tafenoquine in India?
por: Ahmad, Sundus Shafat, et al.
Publicado: (2021)

Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial
por: St Jean, Pamela L., et al.
Publicado: (2016)

Clinical utility of tafenoquine in the prevention of relapse of Plasmodium vivax malaria: a review on the mode of action and emerging trial data
por: Hounkpatin, Aurore B, et al.
Publicado: (2019)

Safety and Efficacy of Tafenoquine for Plasmodium vivax Malaria Prophylaxis and Radical Cure: Overview and Perspectives
por: Markus, Miles B
Publicado: (2021)

Cost-Benefit Analysis of Tafenoquine for Radical Cure of Plasmodium vivax Malaria in Korea
por: Suh, Jiyeon, et al.
Publicado: (2022)

Tafenoquine co-administered with dihydroartemisinin–piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study
por: Sutanto, Inge, et al.
Publicado: (2023)

Estimated impact of tafenoquine for Plasmodium vivax control and elimination in Brazil: A modelling study
por: Nekkab, Narimane, et al.
Publicado: (2021)

Population Pharmacokinetics of Tafenoquine, a Novel Antimalarial
por: Thakkar, Nilay, et al.
Publicado: (2018)

Tafenoquine and primaquine do not exhibit clinical neurologic signs associated with central nervous system lesions in the same manner as earlier 8-aminoquinolines
por: Berman, Jonathan, et al.
Publicado: (2018)

Diagnosis and Treatment of Plasmodium vivax Malaria
por: Baird, J. Kevin, et al.
Publicado: (2016)

Haematological response in experimental human Plasmodium falciparum and Plasmodium vivax malaria
por: Woolley, Stephen D., et al.
Publicado: (2021)

The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: An individual patient data meta-analysis
por: Watson, James A, et al.
Publicado: (2022)

Tafenoquine for the radical cure versus prophylaxis of Plasmodium vivax malaria: the importance of using the appropriate data set
por: Sharma, Raman, et al.
Publicado: (2023)

A randomized, double-blind, active-control trial to evaluate the efficacy and safety of a three day course of tafenoquine monotherapy for the treatment of Plasmodium vivax malaria
por: Fukuda, Mark M., et al.
Publicado: (2017)

Triangular test design to evaluate tinidazole in the prevention of Plasmodium vivax relapse
por: Macareo, Louis, et al.
Publicado: (2013)

Tafenoquine: A 2018 Novel FDA-Approved Prodrug for the Radical Cure of Plasmodium vivax Malaria and Prophylaxis of Malaria
por: Mayence, Annie, et al.
Publicado: (2019)

Efficacy and Safety of Pyronaridine–Artesunate for the Treatment of Uncomplicated Plasmodium falciparum and Plasmodium vivax Malaria in Myanmar
por: Han, Kay Thwe, et al.
Publicado: (2020)

Variation in relapse frequency and the transmission potential of Plasmodium vivax malaria
por: White, Michael T., et al.
Publicado: (2016)

Tafenoquine succinate for malaria prevention
Publicado: (2019)

Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria
por: Watson, James, et al.
Publicado: (2018)

Tafenoquine at therapeutic concentrations does not prolong fridericia-corrected QT interval in healthy subjects
por: Green, Justin A, et al.
Publicado: (2014)

Higher-Dose Primaquine to Prevent Relapse of Plasmodium vivax Malaria
por: Watson, James A., et al.
Publicado: (2022)

Plasmodium vivax and Plasmodium falciparum infection dynamics: re-infections, recrudescences and relapses
por: White, Michael T., et al.
Publicado: (2018)

Plasmodium vivax in Children: Hidden Burden and Conspicuous Challenges, a Narrative Review
por: Drysdale, Myriam, et al.
Publicado: (2022)

Geographical variation in Plasmodium vivax relapse
por: Battle, Katherine E, et al.
Publicado: (2014)

Management of relapsing Plasmodium vivax malaria
por: Chu, Cindy S, et al.
Publicado: (2016)

Randomized Placebo-Controlled Trial Evaluating the Ophthalmic Safety of Single-Dose Tafenoquine in Healthy Volunteers
por: Ackert, Jessica, et al.
Publicado: (2019)

Pharmacokinetic Interactions between Tafenoquine and Dihydroartemisinin-Piperaquine or Artemether-Lumefantrine in Healthy Adult Subjects
por: Green, Justin A., et al.
Publicado: (2016)

Population Pharmacokinetics and Pharmacodynamics of Chloroquine in a Plasmodium vivax Volunteer Infection Study
por: Abd‐Rahman, Azrin N., et al.
Publicado: (2020)

Determinants of relapse periodicity in Plasmodium vivax malaria
por: White, Nicholas J
Publicado: (2011)

Hypnozoite depletion in successive Plasmodium vivax relapses
por: Noviyanti, Rintis, et al.
Publicado: (2022)

Population heterogeneity in Plasmodium vivax relapse risk
por: Stadler, Eva, et al.
Publicado: (2022)

Efficacy of Primaquine in Preventing Short- and Long-Latency Plasmodium vivax Relapses in Nepal
por: Rijal, Komal Raj, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2r2unn45uuqf8v84bltpbp5lkg